Telix Completes BiPASS Enrollment and Aligns With FDA
MELBOURNE, Australia and INDIANAPOLIS, September 2, 2026 Telix Pharmaceuticals Limited has completed enrollment of 350 patients in its Phase...
Telix Pharmaceuticals
Advertisement
Telix Strengthens Radiopharmaceutical Pipeline with Multiple Late-Stage Clinical Milestones
Melbourne, Australia and Indianapolis, Indiana, U.S. | August 20, 2026 Telix Pharmaceuticals reported strong first-half 2026 performance, highlighting continued...
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
Telix Completes Phase 3 Enrollment for Illuccix in Japan
MELBOURNE, Australia, and TOKYO, Japan, July 17, 2026 Telix Pharmaceuticals has completed patient enrollment in its pivotal Phase 3...
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Advertisements
Telix Expands PSMA-PET Imaging in Prostate Cancer Care
MELBOURNE, Australia, and INDIANAPOLIS, May 15, 2026 Telix Pharmaceuticals Limited announced new strategic collaborations with EDAP TMS S.A. and...
Telix Advances TLX597-Tx Phase 2 Prostate Cancer Program
MELBOURNE, Australia & INDIANAPOLIS, IN, April 30, 2026 Telix Pharmaceuticals has announced encouraging dosimetry results from its Phase 2...
Telix Doses First Patient in Phase 3 Glioblastoma Trial
Melbourne, Australia & Indianapolis, Indiana, U.S. | April 15, 2026 Telix Pharmaceuticals has announced a major clinical milestone with...
Telix and Regeneron Partner to Advance Radiopharma Therapies
Melbourne, Australia & Tarrytown, New York | April 13, 2026 Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic...
Telix NDA Accepted for Pixclara Brain Cancer Imaging
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
Advertisement
